This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

25 Jul 2011

BrainStorm and PharmaNet Ink ALS Pact

BrainStorm Cell Therapeutics signs a deal with PharmaNet LLC for BrainStorm’s NurOwn clinical trials in ALS patients.

BrainStorm Cell Therapeutics, a developer of stem cell technologies to provide treatments for currently incurable neurodegenerative diseases, has signed an agreement with PharmaNet LLC, a unit of inVentiv Health Co., to assist in the IND protocol development for the submission of BrainStorm’s NurOwn clinical trials in ALS patients.


The drug was granted Orphan Drug Designation by the FDA as treatment for ALS.


"The agreement with PharmaNet brings us one step closer to obtaining FDA approval for our human clinical trials in the United States,” said Dr. Adrian Harel acting chief executive officer of BrainStorm. “


Related News